logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Aminoketone class drugs

    FiltersReset Filters
    21 results

    • aplenzin

      (bupropion hydrobromide)
      Bausch Health US, LLC
      Usage: APLENZIN (bupropion hydrobromide) is indicated for treating major depressive disorder (MDD) and for the prevention of seasonal major depressive episodes in patients with seasonal affective disorder (SAD). Efficacy has been demonstrated in multiple controlled trials for both indications.

    • auvelity

      (dextromethorphan hydrobromide, bupropion hydrochloride)
      Axsome Therapeutics, Inc.
      Usage: AUVELITY is indicated for the treatment of major depressive disorder (MDD) in adults.

    • bupropion hydrochloride

      (Bupropion hydrochloride)
      Sun Pharmaceutical Industries, Inc.
      Usage: Bupropion hydrochloride extended-release tablets are indicated for treating major depressive disorder (MDD) and preventing seasonal major depressive episodes in patients with seasonal affective disorder (SAD). Efficacy was established in multiple controlled trials for both conditions, as defined by the DSM.

    • bupropion hydrochloride

      (Bupropion Hydrochloride)
      Actavis Pharma, Inc.
      Usage: Bupropion hydrochloride extended-release tablets (XL) are indicated for treating major depressive disorder (MDD) and preventing seasonal major depressive episodes in patients with seasonal affective disorder (SAD). Efficacy was established through controlled clinical trials for both conditions.

    • bupropion hydrochloride

      (Bupropion hydrochloride)
      Granules Pharmaceuticals Inc.
      Usage: Bupropion hydrochloride extended-release tablets (XL) are indicated for treating major depressive disorder (MDD) and preventing seasonal major depressive episodes in seasonal affective disorder (SAD), as established through controlled clinical trials.

    • bupropion hydrochloride

      (bupropion hydrochloride)
      Actavis Pharma, Inc.
      Usage: Bupropion hydrochloride extended-release tablets are indicated for treating major depressive disorder (MDD) in adults. Efficacy has been demonstrated in controlled trials for both acute episodes and maintaining antidepressant response after initial treatment.

    • bupropion hydrochloride

      (Bupropion Hydrochloride)
      Alembic Pharmaceuticals Inc.
      Usage: Bupropion hydrochloride tablets USP are indicated for the treatment of major depressive disorder (MDD) as defined by the DSM, supported by clinical trials demonstrating efficacy in managing major depressive episodes in adults.

    • bupropion hydrochloride

      (bupropion hydrochloride)
      Actavis Pharma, Inc.
      Usage: Bupropion hydrochloride extended-release tablets are indicated as an aid for smoking cessation treatment.

    • bupropion hydrochloride

      (Bupropion Hydrochloride)
      Actavis Pharma, Inc.
      Usage: Bupropion hydrochloride extended-release tablets (XL) are indicated for treating major depressive disorder (MDD) and preventing seasonal major depressive episodes in patients with seasonal affective disorder (SAD). Efficacy is supported by controlled clinical trials for both conditions.

    • bupropion hydrochloride

      (BUPROPION HYDROCHLORIDE)
      Epic Pharma LLC
      Usage: Bupropion hydrochloride extended-release tablets (SR) are indicated for treating major depressive disorder (MDD) in adults. Efficacy was established through controlled trials, showing effectiveness in both short-term treatment and maintenance of antidepressant response for up to 44 weeks.